Ketamine & Related Compounds for Psychiatric Disorders

6th - 8th April 2020: Meeting at Blavatnik School of Government, Oxford, UK

28th March - 8th April:  online e-presentations, webmeetings & live streaming

Glutamatergic antidepressants are starting to disrupt and transform the treatment of psychiatric disorders. Knowledge of their potential is rapidly expanding. As this potential is realised, more questions open up about the details of their use.

Come to Oxford and hear leading researchers, clinicians and policy makers present data from the latest trials and other studies. 
Take part in  The Lancet Psychiatry Debate:  'This house believes that there is sufficient evidence for the wide prescription of ketamine for resistant depression'

Alternatively, if you cannot join us in person, join the conference online - either in real-time or after the event.

Whether you come in person, or join on-line, you can participate in e-presentations.  Instead of standing at conventional posters, you can preview online slide decks or posters and then participate in scheduled Webmeetings and Q&As to discuss the work with presenters.  

Enjoy the flexibility of reviewing recordings of the live-streamed talks and e-presentations at your own convenience.  

Are you a researcher with preclinical data wanting to reach the widest possible online audience? Or a clinician wanting insights from those at the leading edge of practice? Or a psychotherapist wanting to hear how drugs can assist therapy? Or a policy maker thinking about service reconfiguration?  There will be something for you at Ketamine 2020.  Take a look at the programme for the first Oxford conference in 2018.

We look forward to meeting you in Oxford, or online!